Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T02389
|
|||||
Target Name |
HUMAN cysteinyl leukotriene receptor (CysLTR)
|
|||||
Gene Name |
CYSLTR1; CYSLTR2
|
|||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | COVID-19 [ICD-11: 1D6Y] | |||||
Function |
Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system.
Click to Show/Hide
|
|||||
BioChemical Class |
G-protein coupled receptor 1 family
|
|||||
UniProt ID | ||||||
Sequence |
MDETGNLTVSSATCHDTIDDFRNQVYSTLYSMISVVGFFGNGFVLYVLIKTYHKKSAFQV
YMINLAVADLLCVCTLPLRVVYYVHKGIWLFGDFLCRLSTYALYVNLYCSIFFMTAMSFF RCIAIVFPVQNINLVTQKKARFVCVGIWIFVILTSSPFLMAKPQKDEKNNTKCFEPPQDN QTKNHVLVLHYVSLFVGFIIPFVIIIVCYTMIILTLLKKSMKKNLSSHKKAIGMIMVVTA AFLVSFMPYHIQRTIHLHFLHNETKPCDSVLRMQKSVVITLSLAASNCCFDPLLYFFSGG NFRKRLSTFRKHSLSSVTYVPRKKASLPEKGEEICKV Click to Show/Hide
|
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Drugs in Phase 3 Trial | [+] 1 | + | ||||
1 | Montelukast | Drug Info | Phase 2/3 | Coronavirus Disease 2019 (COVID-19) | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Antagonist | [+] 1 Antagonist drugs | + | ||||
1 | Montelukast | Drug Info | [1] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828. | |||||
REF 2 | The COvid-19 Symptom MOntelukast Trial (COSMO) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.